Uncategorized Archives - Page 31 of 163

FridayApr 04, 2025 10:30 am

Adageis Offers Enhanced Transparency in Insurance Payments for Healthcare Providers

The company’s AI-driven software helps clinics transition to value-based care and optimize revenue streams, offering providers superior visibility into insurance contracts and associated reimbursements. Adageis provides advocacy for healthcare organizations, identifying discrepancies in payments and ensuring they are fairly compensated for services. The platform allows providers to assess which insurance contracts align best with their financial goals and patient care priorities, improving financial planning. Healthcare providers often struggle to navigate complex insurance contracts to determine whether they are receiving proper reimbursement for services. A lack of transparency in how the process unfolds can result in lost revenue and financial instability,…

ThursdayApr 03, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment

Soligenix is enrolling patients in its FLASH2 study, with a formal interim analysis anticipated early in 2026. SNGX’s HyBryte is a novel photodynamic therapy using synthetic hypericin activated by safe visible light. The ongoing phase 3 replication study meets stringent requirements of regulatory agencies to strengthen the case for HyBryte as a commercially available treatment. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases and unmet medical needs, is making significant strides in its efforts to bring innovative therapies to patients with early-stage cutaneous T-cell lymphoma (“CTCL”). The company’s lead candidate,…

WednesdayApr 02, 2025 9:45 am

Clene Inc. (NASDAQ: CLNN) to Share CNM-Au8(R) Progress at Jones Las Vegas Conference

The company will present at the Jones Las Vegas Technology and Innovation Conference on April 8-9, to update investors on its lead drug candidate. The conference will provide one-on-one meetings and networking opportunities for institutional investors and executives. Clene recently received FDA guidance on a potential accelerated approval pathway for CNM-Au8 in ALS treatment. New analyses suggest CNM-Au8 improves survival for ALS patients, with a 4.1-month increase in restricted mean survival time. Clene plans to begin enrollment for a Phase 3 confirmatory trial (RESTORE-ALS) in mid-2025. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical…

FridayMar 28, 2025 1:00 pm

Adageis Simplifies Value-Based Care for Healthcare Providers

Adageis makes it easier for providers to identify and obtain the most profitable reimbursements while maintaining high-quality value-based care. The company’s platform enables providers to receive the full payments they deserve by advocating on their behalf with insurers. Adageis offers seamless integration – the platform works with over 90 electronic health record (“EHR”) systems, eliminating the need for disruptive system changes. The company is working with investors to develop new solutions to support small and independent healthcare practices. Healthcare providers often struggle with complex reimbursement structures, making it difficult to optimize cash flow while ensuring high-quality value-based patient care. Adageis…

ThursdayMar 27, 2025 9:45 am

Clene Inc.’s (NASDAQ: CLNN) Q1 Virtual Investor Summit Presentation Available for On-Demand Viewing

Clene’s presentation by CEO Rob Etherington and CFO Morgan Brown is now available on demand on the event’s website, covering the company’s recent achievements and immediate plans for lead drug candidate CNM-Au8®. Clene is planning to submit a New Drug Application (“NDA”) to the FDA for potential accelerated approval for CNM-Au8 for ALS in the second half of 2025. The company recently released the latest data from a cross-regimen analysis of HEALEY ALS Platform Trial, showing that CNM-Au8 significantly extends survival in patients with ALS. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical…

WednesdayMar 26, 2025 2:20 pm

Meeting the Healthcare Demands of America’s Growing AAPI Elderly Population

A Strategic Approach to Addressing a Critical Demographic Shift Mrs. Lin, a 72-year-old Korean-American retiree, has lived in the same neighborhood for decades. She visits her longtime physician, a trusted figure in the community, for regular checkups. However, with many private-practice doctors retiring and younger physicians moving into large corporate healthcare settings, she now struggles to navigate an unfamiliar system that doesn’t always cater to her cultural and linguistic needs. Her story reflects a growing challenge for AAPI seniors across the country as the healthcare system struggles to keep pace with their specific needs. By 2060, the number of Asian…

ThursdayMar 20, 2025 9:00 am

Adageis on Track to Exceed Q1 Growth Target, Expanding Healthcare AI Platform

Adageis is surpassing its Q1 2025 growth targets, reflecting expanding market demand, with investment focused on team expansion, financial infrastructure, and AI development. Adageis’ patented AI-driven platform, already covering over 250,000 patient lives, optimizes quality healthcare for patients and revenue for healthcare providers. The company projects 580,000 patient lives covered by the end of Q2 2025. Adageis, a healthcare technology company reshaping patient care through flexible AI-centric software solutions for healthcare organizations, is set to exceed its Q1 2025 growth expectations as its AI-powered platform continues to gain traction in the healthcare sector. The company now covers more than 250,000…

WednesdayMar 19, 2025 9:00 am

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Delivers Significant Survival Benefits in New Analyses of Healey ALS Platform Trial Data

Clene's CNM-Au8® treatment was demonstrated to improve survival in ALS patients by up to 14.8 months. The findings come from a post hoc analysis of the HEALEY ALS Platform Trial, comparing CNM-Au8 to a concurrently enrolled control. Strong survival benefit was observed in patients meeting the planned criteria for Clene’s upcoming Phase 3 RESTORE-ALS trial. The company is preparing to submit a New Drug Application (“NDA”) to the FDA later this year for potential accelerated approval, and further regulatory discussions and a confirmatory Phase 3 trial are planned for mid-2025. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine…

FridayMar 14, 2025 9:00 am

Adageis to Launch Series A Funding Round, Seeking $10M in Growth Capital

Adageis is opening a Series A funding round, capital raise, aiming to raise $10 million for growth and expansion. The company previously closed a $2 million seed round in Q4 2024 to enhance operations and market reach. Adageis expects to exceed growth targets for Q1 2025, with strong market adoption of its AI-powered platform designed to streamline healthcare operations, optimize revenue, and improve patient care outcomes. The company has cut onboarding time from four weeks to one week, accelerating customer acquisition and revenue growth. Adageis, a healthcare technology company reshaping patient care through flexible AI-centric software solutions for healthcare organizations,…

ThursdayMar 13, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’

Soligenix has multiple late-stage assets with orphan and fast-track designations, providing a clear regulatory pathway toward potential approvals. The company’s pipeline has a total addressable market exceeding $2 billion, spanning rare diseases, inflammation, and biothreat applications. Soligenix has benefited from significant non-dilutive government funding, which reduces operational expenses and financial risk while supporting its public health initiatives. The company is well-positioned for multiple development and regulatory catalysts, and commercial milestones, with lead candidates in cutaneous T-cell lymphoma, psoriasis, oral mucositis, and Behçet’s disease. Soligenix is led by an experienced management team with a strong track record of success. Soligenix (NASDAQ:…